Aviragen Therapeutics (AVIR) traded down $0.03 during mid-day trading on Tuesday, hitting $0.58. 534,715 shares of the company traded hands, compared to its average volume of 1,326,173. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.76 and a quick ratio of 6.76.
ILLEGAL ACTIVITY WARNING: “Aviragen Therapeutics, Inc. (AVIR) Earns “Hold” Rating from HC Wainwright” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/03/aviragen-therapeutics-inc-avir-earns-hold-rating-from-hc-wainwright.html.
Hedge funds have recently added to or reduced their stakes in the company. Carlson Capital Management acquired a new stake in Aviragen Therapeutics in the 2nd quarter valued at $105,000. Virtu KCG Holdings LLC acquired a new stake in Aviragen Therapeutics in the 2nd quarter valued at $149,000. Finally, FMR LLC increased its holdings in Aviragen Therapeutics by 115.3% in the 1st quarter. FMR LLC now owns 1,002,500 shares of the biotechnology company’s stock valued at $653,000 after purchasing an additional 536,799 shares in the last quarter. Institutional investors and hedge funds own 24.20% of the company’s stock.
About Aviragen Therapeutics
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.
What are top analysts saying about Aviragen Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aviragen Therapeutics Inc. and related companies.